Cheplapharm Sees Revenue Growth in 2025

In 2025, Cheplapharm reported an 8.1% increase in revenue, reaching €1,658.4 million, compared to €1,534.6 million in 2024. EBITDA remained stable at €642.8 million, resulting in an industry-leading EBITDA margin of 38.8%. The company's workforce grew slightly, reaching 799 employees by year-end.

Cheplapharm, known for acquiring established pharmaceutical products, has secured its financial future by successfully placing two bonds with long maturities. This move has provided the company with financial stability and planning flexibility.

Cheplapharm plans to continue capitalizing on the strong market trend for branded medicines, positioning itself for further growth. The Greifswald-based company has steadily grown over the past two decades, establishing itself as a global leader in its sector.